)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
GenSight Biologics
GenSight Biologics (SIGHT) investor relations material
GenSight Biologics Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary7 Oct, 2026
Executive summary
Cash and cash equivalents were €0.7 million at September 30, 2026; paid early access programs generated €8.2 million in gross collections since treatments began in March.
Funding is insufficient for the next 12 months without additional financing or cash inflows; the estimated net funding requirement is €16 million, mainly for RECOVER Phase III preparation and manufacturing.
Financial highlights
Cash and cash equivalents were €0.7 million at September 30, 2026, versus €1.7 million at June 30, 2026.
Q3 gross collections from the French named patient early access program were €1.7 million; cumulative gross collections reached €8.2 million from March 2026.
Collections are reported gross of rebates; the quarterly cash decrease reflected the summer treatment pause, manufacturing technology transfer and RECOVER preparation.
Outlook and guidance
Treatments through paid early access programs in new countries are expected in Q4 2026.
With bridge financing of up to €2 million or additional early access cash inflows secured by end-November 2026, available resources are projected to last until late March 2027.
First significant RECOVER preparation payments are due in late March 2027; without structural financing by then, the trial start would be postponed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from GenSight Biologics
- Early-access proceeds bolster cash, while RECOVER costs remain outside expected 2026 coverage.SIGHT
Q1 2026 TU - Early-access proceeds support 2026 operations as RECOVER and manufacturing readiness advance.SIGHTQ2 2026 TU
- Negative reported revenue and increased net loss highlight urgent funding needs.SIGHTH1 2026
- Net loss narrowed 14% to €12M in 2025, but further funding is needed for Phase III trial.SIGHTH2 2025
- Year-end cash rose to €2.4M, with new funds and early access revenues supporting 2026 plans.SIGHTQ4 2025 TU
- Cash position strengthened by fundraising, but runway depends on regulatory outcomes.SIGHTQ3 2025 TU
- Net loss widened to €7.0M, cash outflow fell 8.3%, and runway extends to late Q4 2025.SIGHTH1 2025
- Cash position extended to October 2025; key regulatory and manufacturing milestones achieved.SIGHTQ2 2025 TU
- Net loss narrowed and cash burn halved, but going concern risk persists amid pending AAC/CAP restart.SIGHTH1 2024
Next GenSight Biologics earnings date
H2 202630 Mar, 2027
GenSight Biologics
Next GenSight Biologics earnings date
H2 202630 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
GenSight Biologics SA is a French biotechnology company focused on developing gene therapies for neurodegenerative diseases affecting vision. The company's primary area of research involves treatments for inherited retinal diseases, including Leber Hereditary Optic Neuropathy (LHON), a condition that leads to sudden vision loss. GenSight Biologics uses proprietary gene therapy platforms to target and potentially restore function in damaged retinal cells. Its therapies are designed to offer long-lasting effects with a single administration. The company is headquartered in Paris, France, and its shares are listed on Euronext Paris.